A 3D Bioprinting Stock That’s Not Organovo

April 1. 2019. 6 mins read

One thing we’ve noticed over the years is that the way we imagine a disruptive technology being commercialized is rarely how things actually transpire. We’re seeing that now as 3D printing business models and technologies evolve over time into something different. The same can be said for the companies that are involved in disruptive technologies where things move fast and investors expect things to happen quickly. If you don’t move quickly to commercialize a new technology at scale, there are plenty of companies that will gladly fill that void.

It’s been a while since we’ve looked at 3D bioprinting, a disruptive technology that we imagined would involve 3D printing replacement organs for the human body. One of the most promising stocks back in the day was a company called Organovo (ONVO). We’ve written a number of articles about the firm, the last being an article titled “An Organovo Article With a Negative Spin” which pointed out how the company seemed overly focused on the way they were being perceived by the media. It’s understandable why a firm would be focused on investor relations, especially if they’re being attacked by short sellers for example. Still, it’s hard not to be thinking negative things about Organovo as we all wait for the revenue growth to happen. From our last article:

On the first day of 2012, Organovo had 22.4 million shares outstanding and since then that number has risen to 81.5 million. With the shares outstanding having nearly quadrupled, investors can take some solace in the fact that Organovo has $50

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.